title: Radiation Safety Precautions in (131)I Therapy of Graves' Disease Based on Actual Biokinetic Measurements.
abstract: BACKGROUND
  Radiation protection is an integral part of targeted radionuclide therapy. How to offer rational radiation precautions to patients with Graves' disease (GD) undergoing (131)I therapy is still a matter of ongoing discussions.
  
  
  OBJECTIVE
  The objective of the study was to formulate radiation precautions for GD patients undergoing (131)I therapy through actual biokinetic measurements for a particular population of patients.
  
  
  METHODS
  This was a prospective study.
  
  
  METHODS
  The study was conducted at a university hospital.
  
  
  METHODS
  From January 2009 through January 2012, consecutive GD patients prepared for (131)I therapy were prospectively recruited.
  
  
  METHODS
  Pretherapy thyroid radioiodine uptake and uptake ratio (4 to 24 h radioiodine uptake) were measured. Serial whole-body dose-rate measurements after therapy were performed to deduce (131)I whole-body retention. Calculations based on deduced whole-body retention and measured thyroid radioiodine biokinetics were derived to determine the thyroidal and extrathyroidal compartment uptake fractions and effective half-lives. Precaution times necessary to avoid close contact with family members and the general public were derived from these parameters and regulatory dose limits.
  
  
  RESULTS
  A total of 72 patients were eligible for the analysis. A high interpatient variability in (131)I biokinetics was observed: the mean peaking (131)I uptake (±1 SD) in the thyroid was 68% (±19%), and the range was 18%-89%; the mean effective (131)I half-life (±1 SD) in the remainder of the body was 5.1 (±0.9) hours (range 3.5-7.2 h). The mean measured initial dose rate (±1 SD) at 1.0 m after (131)I administration was 0.039 (±0.003) μSv·h(-1) · MBq(-1) (range 0.017-0.055 μSv·h(-1) · MBq(-1)). The 0.3:1.0 m initial dose rate ranged from 2.9 to 7.1, which was greatly lower than the projected ratio of 11.1 by the inverse square law approximation. On the basis of the measured radioiodine biokinetics and dose rates, detailed instructions were provided to limit nearby individuals' exposure.
  
  
  CONCLUSIONS
  The use of actual biokinetic measurements may remove the effect of variability errors associated with general default assumptions about the (131)I biokinetics in GD patients. The marked variability in (131)I biokinetics among GD patients reinforces the need for patient-specific iodine biokinetic measurements for radiation safety precautions.
authors.affiliation: Departments of Nuclear Medicine (B.L., R.T., W.P., R.H., A.K.) and Ultrasonography (Y.H.), West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Liu
authors.affiliation: Departments of Nuclear Medicine (B.L., R.T., W.P., R.H., A.K.) and Ultrasonography (Y.H.), West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Rong
authors.initials: R
authors.lastname: Tian
authors.affiliation: Departments of Nuclear Medicine (B.L., R.T., W.P., R.H., A.K.) and Ultrasonography (Y.H.), West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Weiai
authors.initials: W
authors.lastname: Peng
authors.affiliation: Departments of Nuclear Medicine (B.L., R.T., W.P., R.H., A.K.) and Ultrasonography (Y.H.), West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: He
authors.affiliation: Departments of Nuclear Medicine (B.L., R.T., W.P., R.H., A.K.) and Ultrasonography (Y.H.), West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Huang
authors.affiliation: Departments of Nuclear Medicine (B.L., R.T., W.P., R.H., A.K.) and Ultrasonography (Y.H.), West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Anren
authors.initials: A
authors.lastname: Kuang
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006111:Graves Disease / Q000453:epidemiology / Q000378:metabolism / Q000532:radiotherapy*; D006207:Half-Life; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D061214:Patient Safety / Q000592:standards*; D011832:Radiation Injuries / Q000453:epidemiology / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D011835:Radiation Protection / Q000592:standards*; D011879:Radiotherapy Dosage; D013961:Thyroid Gland / Q000378:metabolism / Q000473:pathology; D055815:Young Adult
chemical_list: D007457:Iodine Radioisotopes